UNSPSC 51262411: Procaterol hydrochloride

This classification denotes an adrenergic beta-2 receptor agonist C16H22N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4VD1BRT7T8, chemically known as 2(1h)-quinolinone, 8-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-, monohydrochloride, (r*,s*), (+/-)-, but more generally known as procaterol hydrochloride, which bears US NIH Compound Identifier 43091. European Medicines Agency schedules Procaterol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04050MIG.

Most nations, for tariff and trade purposes, schedule procaterol hydrochloride under HS 29337900 and SITC 51561. As of Q4 2014, PROCATEROL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H]([C@H](C1CCC(C2C1CCC(=O)[NH]2)O)O)NC(C)C.CL.

UNSPSC 51262411 Procaterol hydrochloride is a Commodity code that, based on recent state and local opportunities, does not align with the pharmaceutical products actually being solicited under this classification. The most recent opportunities tagged to this code involve naloxone acquisition and direct-to-manufacturer pharmacy programs, neither of which are procaterol hydrochloride, a selective beta-2 agonist bronchodilator. The mismatch suggests either a tagging error in the source data or a commodities taxonomy lag. State and local procurement under this code shows minimal relevant recent activity; when opportunities do appear, they reflect broader pharmaceutical sourcing and healthcare supply chain initiatives rather than procurement of procaterol hydrochloride specifically.

Geographic activity centers on Florida and Texas, based on the most recent postings. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for its pharmacy benefit initiative. Both issuing bodies are state or county-level health agencies, though the opportunities themselves do not reflect procurement of procaterol hydrochloride. Firms tracking this code should verify whether the UNSPSC classification is correctly applied to their target market or whether parallel pharmaceutical sourcing codes better match their product portfolio.